A Propensity Score Matching Analysis of Dasatinib and Nilotonib as a Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase

BACKGROUND: Both dasatinib and nilotinib are approved frontline therapy for chronic myeloid leukemia, chronic phase (CML-CP) based on randomized trials compared to imatinib. However, no head to head comparison of dasatinib and nilotinib has been conducted in newly diagnosed CML-CP patients. METHOD:...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Takahashi, Koichi, Kantarjian, Hagop, Yang, Yulong, Sasaki, Koji, Jain, Preetesh, DellaSala, Sara, Ravandi, Farhad, Kadia, Tapan, Pemmaraju, Naveen, Daver, Naval, Borthakur, Gautam, Garcia-Manero, Guillermo, Jabbour, Elias, Cortes, Jorge E.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5073019/
https://ncbi.nlm.nih.gov/pubmed/27509035
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30197
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars